Cancer Immunology, Immunotherapy

, Volume 31, Issue 4, pp 197–201 | Cite as

Effects of methotrexate-carcinoembryonic-antigen-antibody immunoconjugates on GW-39 human tumors in nude mice

  • Lisa B. Shih
  • David M. Goldenberg
Original articles


Methotrexate (MTX) was conjugated to an anti-carcinoembryonic antigen monoclonal antibody (NP2) by using amino-dextran as an intermediate carrier. The drug was chemically linked to amino-dextran (averageMr = 40000), and the resulting MTX-dextran was then site-specifically attached to the carbohydrate moiety of the antibody. Athymic nude mice that carried human colonic GW-39 tumors (s. c.) were treated with the immunoconjugate. In this study, the specific conjugate caused a greater inhibition of the tumor growth than either free MTX or its conjugate with dextran and an irrelevant antibody. The intermediate MTX-dextran and the unlinked mixture of MTX-dextran with NP2 were both relatively ineffective in inhibiting tumor growth. The greatly reduced host toxicity permitted the use of the MTX-dextran-NP2 in a high-dose therapy of this tumor system.


Tumor Growth Methotrexate Dextran Nude Mouse Human Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Arnon R, Sela M (1982) In vitro and in vivo efficacy of conjugates of daunomycin with anti-tumor antibodies. Immunol Rev 62: 5PubMedGoogle Scholar
  2. 2.
    Baldwin RW, Embleton MJ, Garnett MC, Pimm MV (1987) Conjugates of monoclonal antibody 791T/36 with methotrexate in cancer therapy. NCI Monogr 3: 95PubMedGoogle Scholar
  3. 3.
    Dillman RO (1987) Antibody therapy. In: Oldham RK (ed) Principles of cancer biotherapy. Raven Press, New York, p 291Google Scholar
  4. 4.
    Dillman RO, Johnson DE, Shawler DL, Koziol JA (1988) Superiority of an acid-labile daunomycin-monoclonal antibody immunoconjugate compared to free drug. Cancer Res 48: 6097PubMedGoogle Scholar
  5. 5.
    Durrant LG, Garnett MC, Gallego J, Armitage NC, Ballantyne KC, Marksman RA, Hardcastle JD, Baldwin RW (1987) Sensitivity of newly established colorectal cell lines to cytotoxic drugs and monoclonal antibody drug conjugates. Br J Cancer 56: 722PubMedGoogle Scholar
  6. 6.
    Endo N, Kato Y, Takeda Y, Saito M, Umemoto N, Kishida K, Hara T (1987) In vitro cytotoxicity of a human serum albumin-mediated conjugate of methotrexate with anti-MM46 monoclonal antibody. Cancer Res 47: 1076PubMedGoogle Scholar
  7. 7.
    Endo N, Takeda Y, Kishida K, Kato Y, Saito M, Umemoto N, Hara T (1987) Target-selective cytotoxicity of methotrexate conjugated with monoclonal anti-MM46 antibody. Cancer Immunol Immunother 25: 1PubMedGoogle Scholar
  8. 8.
    Epenetos AA, Snook D, Durban H, Johnson PM, Taylor-Papadimitrion J (1986) Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res 46: 3183PubMedGoogle Scholar
  9. 9.
    Garnett MC, Baldwin RW (1986) An improved synthesis of a methotrexate-791T/36 monoclonal antibody conjugate cytotoxic to human osteogenic sarcoma cell lines. Cancer Res 46: 2407PubMedGoogle Scholar
  10. 10.
    Garnett MC, Embleton MJ, Jacobs E, Baldwin RW (1983) Preparation and properties of a drug-carrier-antibody conjugate showing selective antibody-directed cytotoxicity in vitro. Int J Cancer 31: 661PubMedGoogle Scholar
  11. 11.
    Goldenberg DM, Ammersdorfer E (1970) Synergistic effects of x-rays and drugs on a human tumor xenograft, GW-39. Eur J Cancer 6: 73PubMedGoogle Scholar
  12. 12.
    Goldenberg DM, Hansen HJ (1972) Carcinoembryonic antigen present in human colonic neoplasia serially propagated in hamsters. Science 175: 1117PubMedGoogle Scholar
  13. 13.
    Goldenberg DM, Witte S, Elster K (1966). GW-39: a new human tumor serially transplantable in the golden hamster. Transplantation 4: 760PubMedGoogle Scholar
  14. 14.
    Goldenberg DM, Goldenberg H, Sharkey RM, Lee RE, Higginbotham-Ford E, Horowitz JA, Hall TC, Pinsky CM, Hansen HJ (1989) Imaging of colorectal carcinoma with radiolabeled antibodies. Semin Nucl Med 19: 262PubMedGoogle Scholar
  15. 15.
    Hurwitz E, Levy R, Maron R, Wilchek M, Arnon R, Sela M (1975) The covalent binding daunomycin and Adriamycin to antibodies with retention of both drug and antibody activities. Cancer Res 35: 1175PubMedGoogle Scholar
  16. 16.
    Hurwitz E, Maron R, Bernstein A, Wilchek M, Sela M, Arnon R (1978) The effect in vivo of chemotherapeutic drug-antibody conjugates in two murine experimental tumor systems. Int J Cancer 21: 747PubMedGoogle Scholar
  17. 17.
    Kanellos J, Pietersz GA, McKenzie IFC (1985) Studies of methotrexate-monoclonal antibody conjugates for immunotherapy. J Natl Cancer Inst 75: 319PubMedGoogle Scholar
  18. 18.
    Kulkarni PN, Blair AH, Ghose TI (1981) Covalent binding of methotrexate to immunoglobulins and the effect of antibody-linked drug on tumor growth in vivo. Cancer Res 41: 2700PubMedGoogle Scholar
  19. 19.
    Manabe Y, Tsubota T, Haruta Y, Kataoka K, Okazaki M, Haisa S, Nakamura K, Kimura I (1984) Production of a monoclonal antibody-methotrexate conjugate utilizing dextran T-40 and its biological activity. J Lab Clin Med 104: 445PubMedGoogle Scholar
  20. 20.
    Sharkey RM, Primus FJ, Shochat D, Goldenberg DM (1988) Comparison of tumor targeting of mouse monoclonal and goat polyclonal antibodies to carcinoembryonic antigen in the GW-39 human tumorhamster host model. Cancer Res 48: 1823PubMedGoogle Scholar
  21. 21.
    Sharkey RM, Goldenberg DM, Goldenberg H, Lee RE, Ballance C, Pawlyk D, Varga D, Hansen HJ (1990) Murine monoclonal antibodies against carcinoembryonic antigen: immunological, pharmacokinetic, and targeting properties in humans. Cancer Res (in press)Google Scholar
  22. 22.
    Shih LB, Sharkey RM, Primus FJ, Goldenberg DM (1988) Site-specific linkage of methotrexate to monoclonal antibodies using an intermediate carrier. Int J Cancer 41: 832PubMedGoogle Scholar
  23. 23.
    Sokal RR, Rohlf FJ (1969) Biometry. Freeman, San Francisco, pp 226–235Google Scholar
  24. 24.
    Sokal RR, Rohlf FJ (1969) Statistical tables. Freeman, San Francisco, p 159Google Scholar
  25. 25.
    Trouet A, Masquelier M, Baurain R, Deprez-De Campeneere (1982) A covalent linkage between daunorubicin and protein that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies. Proc Natl Acad Sci USA 79: 626Google Scholar
  26. 26.
    Tsukada Y, Kato Y, Umemoto N, Takeda Y, Hara T, Hirai H (1984) An anti-α-fetoprotein antibody-daunomycin conjugate with a novel polyl-glutamic acid derivatives as intermediate drug carrier. J Natl Cancer Inst 73: 721PubMedGoogle Scholar
  27. 27.
    Yang HM, Reisfeld RA (1988) Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice. Proc Natl Acad Sci USA 85: 1189sGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • Lisa B. Shih
    • 1
  • David M. Goldenberg
    • 1
  1. 1.Center for Molecular Medicine and ImmunologyUniversity of Medicine and Dentistry of New JerseyNewarkUSA

Personalised recommendations